Pliant Therapeutics Inc (PLRX) - Total Liabilities
Based on the latest financial reports, Pliant Therapeutics Inc (PLRX) has total liabilities worth $37.43 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Pliant Therapeutics Inc to track the company's year-over-year net asset growth rate.
Pliant Therapeutics Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Pliant Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Pliant Therapeutics Inc generate to measure how efficiently the company converts operating cash flow to free cash.
Pliant Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Pliant Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RBZ Jewellers Limited
NSE:RBZJEWEL
|
India | Rs1.86 Billion |
|
Akoya Biosciences Inc
NASDAQ:AKYA
|
USA | $118.54 Million |
|
Transindia Real Estate Limited
NSE:TREL
|
India | Rs938.30 Million |
|
CONCORD ENVIRO SYSTEMS L
NSE:CEWATER
|
India | Rs3.66 Billion |
|
HY Energy Group Co Ltd
SHG:600387
|
China | CN¥924.38 Million |
|
Gohigh Data Networks Technology Co Ltd
SHE:000851
|
China | CN¥3.80 Billion |
|
Intermediate Capital Group PLC
LSE:ICG
|
UK | GBX7.21 Billion |
|
Wanshih Electronic Co Ltd
TWO:6134
|
Taiwan | NT$997.63 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Pliant Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Pliant Therapeutics Inc (PLRX) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pliant Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pliant Therapeutics Inc (2017–2025)
The table below shows the annual total liabilities of Pliant Therapeutics Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $44.02 Million | -52.60% |
| 2024-12-31 | $92.87 Million | +140.73% |
| 2023-12-31 | $38.58 Million | +3.51% |
| 2022-12-31 | $37.27 Million | +68.22% |
| 2021-12-31 | $22.16 Million | +77.75% |
| 2020-12-31 | $12.46 Million | -89.57% |
| 2019-12-31 | $119.50 Million | +77.27% |
| 2018-12-31 | $67.41 Million | +2014.52% |
| 2017-12-31 | $3.19 Million | -- |
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform c… Read more